医学
阿替唑单抗
溶瘤病毒
乳腺癌
肿瘤科
内科学
癌症
免疫疗法
彭布罗利珠单抗
作者
Tomás Pascual,Juan Miguel Cejalvo,Mafalda Oliveira,Maria Vidal,Estela Vega,Sergi Ganau,Ana Julve,Esther Zamora,I. Miranda,Ana R. Delgado,Begoña Bermejo,Luis Merino,Manel Juan,Juan M Ferrero-Cafiero,Jordi Canes,Xavier Gonzalez,Patricia Villagrasa,Aleix Prat
出处
期刊:Future Oncology
[Future Medicine]
日期:2020-07-07
卷期号:16 (24): 1801-1813
被引量:8
标识
DOI:10.2217/fon-2020-0246
摘要
New treatment strategies such as immune checkpoint inhibitors and oncolytic viruses are opening new possibilities in cancer therapy. Preliminary results in melanoma and other tumors showed that the combination of talimogene laherparepvec with an anti-PD-1/PD-L1 or anti-CTLA4 has greater efficacy than either therapy alone, without additional safety concerns beyond those expected for each agent. The presence of residual cancer after neoadjuvant chemotherapy in early breast cancer patients is an unmet medical need. SOLTI-1503 PROMETEO is a window of opportunity trial, which evaluates the combination of talimogene laherparepvec in combination with atezolizumab in women with operable HER2-negative breast cancer who present residual disease after neoadjuvant chemotherapy. The primary end point is the rate of residual cancer burden 0/1. Clinical Trial Registration: NCT03802604
科研通智能强力驱动
Strongly Powered by AbleSci AI